A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesGuidelines for the management of myeloproliferative neoplasmsAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsAdvances in the management of myelofibrosisThe evolving treatment paradigm in myelofibrosisPractical management of classical myeloproliferative disorder patients: a clinician's guideThalidomide for the treatment of idiopathic myelofibrosis.Modern management of myelofibrosis.Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.A phase-2 trial of low-dose pomalidomide in myelofibrosis.Immunomodulatory agents in myelofibrosis.Emerging drugs for myelofibrosis.Ruxolitinib: a new treatment option for myelofibrosis.Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Thalidomide treatment in a myelofibrosis patient with leukemia transformation.Long-term results of prednisone treatment for the anemia of myelofibrosis.Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.Outcome of transplantation for myelofibrosis.Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemiaJAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaChoosing between stem cell therapy and drugs in myelofibrosis.Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.Profile of pomalidomide and its potential in the treatment of myelofibrosis.The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Thalidomide for the treatment of multiple myeloma.Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Thalidomide and immunomodulatory drugs in the treatment of cancer.Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.Ruxolitinib for myelofibrosis.Allogeneic stem cell transplantation as treatment for myelofibrosis.The evolving role of lenalidomide in the treatment of hematologic malignancies.
P2860
Q26752940-05595ADF-E59D-4C2A-BABA-3B03A07DBBFAQ26778326-B10475D8-7EAE-4A31-9918-83F1DAF0126AQ26863610-650ED28B-1F1D-4D0F-81AF-828C60C6DA60Q27008072-B6313502-B8FD-4DA9-9C0B-A6568572C378Q27021968-860CE6BC-4168-44AD-8D8A-D90012FC03E9Q28200207-01439E03-491B-4BFC-9BD2-A613B9CB375FQ33359542-B54A3F0C-A61A-4983-A5C7-4615E8257413Q33365122-6D2900E1-ACF5-4F74-B5BB-2D2152C5DF83Q33386057-2BF35E05-16E9-4955-8F77-EC5A9D909337Q33392689-458791E3-44F4-4474-A537-7E47FEC30C81Q33401615-13085567-1D3F-4B52-AF29-B903BCD7B1E0Q33404574-9481FAA8-D015-446B-AD42-73F928F5E6E0Q33405241-3E5865F7-9B17-4F5C-88EE-1C49232ECAE2Q33406035-10BC69C5-FED9-4728-BDDC-2327FF3F747CQ33411894-820F7271-FA8E-4E34-8CC0-8A645D3F1115Q33422565-60B24A35-3837-405E-AF3E-10BAF6318A2DQ33423956-5C5C05C1-6D79-4DE6-91D3-0B8958CC8C7BQ33430113-3F3B76E4-0AC0-4587-BD7C-49C419A9B57EQ33432285-F9788B28-4743-4DFC-BF55-CD68BFC2CAF2Q33432406-180D7E6F-77D3-4337-AD43-15744432DE9BQ34015474-46DD3F9E-3086-4F33-A4AE-1B2A22BC80F2Q34146512-86420A25-2211-43F1-9E16-924ACCDF923EQ34150008-2936E43A-FBC3-48F9-BBE9-FB12B5C6FF0BQ34162867-CBF76136-9D2D-4DE9-8358-FC977FE1F9B6Q34165935-102CBDA1-FB51-4BFC-BFF6-EA4E0FC7BBFBQ34253548-374CB751-C24E-4C58-89E1-2EFB1C8C72D6Q34302770-687A61C8-89E0-4BFA-983B-51B7603E8DC9Q34512203-B91EC15D-2B24-4719-A3C1-29D26F2CE90BQ34734491-24CE8AA5-4E7B-4E8C-B1F7-68CBD6A48243Q35203067-80502F79-7161-41BC-8521-28C366415D19Q35427915-D002C014-4F78-4450-8EAF-65F1C96FA9E3Q35849342-7AEA6307-7656-4D62-8D5A-2FA7CD1E75A4Q35870500-9E101DFE-DD95-4450-8A55-F1C5E4C5452CQ35937081-FDFE790E-36DE-4D50-9EC7-EFBFD1547B92Q36001930-199652EE-8EAC-46ED-AF77-E4C4BDE0F779Q36040871-257CC089-BACC-4D52-B064-B6B3A8AF43AEQ36047069-43682259-E60E-45E0-95A2-CE0397BEC8B5Q36604028-9285C731-F076-486D-9B99-4C6C81A8EFF7Q36609417-7AED285A-E29B-40B9-B115-B0567F9326C6Q36739807-748788E8-D51C-40B9-8202-F430B78D031C
P2860
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@ast
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@en
type
label
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@ast
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@en
prefLabel
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@ast
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@en
P2093
P1433
P1476
A phase 2 trial of combination ...... rosis with myeloid metaplasia.
@en
P2093
Animesh Pardanani
Chin-Yang Li
Georgene Schroeder
Gregory Wiseman
Jerome B Zeldis
Leigh A Gray
Michelle Elliott
Ruben A Mesa
Scott H Kaufmann
Terra Reeder
P304
P356
10.1182/BLOOD-2002-09-2928
P407
P577
2002-11-27T00:00:00Z